SCHEMBL24257769

SCHEMBL24257769

Cc1c(-c2cccc(F)c2)cnc(C#N)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
SQOR Q9Y6N5 1/20 0.40
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
CHEK1 O14757 1/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ADORA2B P29275 2/20 0.37
ADORA1 P30542 2/20 0.37
FFAR1 O14842 1/20 0.36
ADORA2A P29274 1/20 0.36
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546869 1.00 C5AR1 (0.41) C5AR1NPSR1KDM4EHPGDRXFP1
SCHEMBL24257768 0.89 SQOR (0.42) KDM4EHPGDSQORGABRG2GABRB3
SCHEMBL30452737 0.87 GRM5 (0.42) KDM4EHPGDSQORGABRG2GABRB3
SCHEMBL24257771 0.87 GRM5 (0.42) KDM4EHPGDSQORGABRG2GABRB3
SCHEMBL24257562 0.86 MAOB (0.47) C5AR1HPGDSQORPDE4APDE4B
SCHEMBL30546831 0.86 MAOB (0.47) C5AR1HPGDSQORPDE4APDE4B
SCHEMBL24257522 0.86 SQOR (0.40) KDM4EHPGDSQORGABRG2GABRB3
SCHEMBL30546879 0.83 HSD17B10 (0.43) KDM4EHPGDSQORADORA1ADORA2A
SCHEMBL24257819 0.83 HSD17B10 (0.43) KDM4EHPGDSQORADORA1ADORA2A
SCHEMBL24257777 0.83 MAPT (0.42) KDM4EHPGDSQORMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 C5AR1 4044/4885NPSR1 4748/4885KDM4E 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.